Listen to the episode on your favorite platforms:
Scrip senior writer Joseph Haas and PwC analyst Roel Van den Akker look back on biopharma sector dealmaking in 2025, why deal values rose from 2024's lows, and look ahead to what the trends mean heading into 2026 in this latest edition of the Scrip M&A Podcast.
Smart linkhttps://pc.st/e/0kiD-U8~Y.P
Official sitehttps://www.citeline.com/
Auto-openhttps://pc.st/e/0kiD-U8~Y.P?a
Add podcast to the siteEmbed Podcast